QR-koodi

Canagliflozin extends life span in genetically heterogeneous male but not female mice

Canagliflozin (Cana) is an FDA-approved diabetes drug that protects against cardiovascular and kidney diseases. It also inhibits the sodium glucose transporter 2 by blocking renal reuptake and intestinal absorption of glucose. In the context of the mouse Interventions Testing Program, genetically he...

Täydet tiedot

Tallennettuna:
Päätekijät: Richard A. Miller, David E. Harrison, David B. Allison, Molly Bogue, Lucas Debarba, Vivian Diaz, Elizabeth Fernandez, Andrzej Galecki, W. Timothy Garvey, Hashan Jayarathne, Navasuja Kumar, Martin A. Javors, Warren C. Ladiges, Francesca Macchiarini, James Nelson, Peter Reifsnyder, Nadia A. Rosenthal, Marianna Sadagurski, Adam B. Salmon, Daniel L. Smith Jr., Jessica M. Snyder, David B. Lombard, Randy Strong
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society for Clinical investigation 2020-11-01
Sarja:JCI Insight
Aiheet:
Aging
Linkit:https://doi.org/10.1172/jci.insight.140019
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia